RT Book, Section
A1 Sepesi, Boris
A1 Hofstetter, Wayne L.
A1 Swisher, Stephen
A2 Morita, Shane Y.
A2 Balch, Charles M.
A2 Klimberg, V. Suzanne
A2 Pawlik, Timothy M.
A2 Posner, Mitchell C.
A2 Tanabe, Kenneth K.
SR Print(0)
ID 1145761294
T1 Multimodality Therapy for Esophageal Cancer: Western Experience Including Definitive Chemoradiation
T2 Textbook of Complex General Surgical Oncology
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9780071793315
LK accesssurgery.mhmedical.com/content.aspx?aid=1145761294
RD 2024/04/19
AB The  incidence  of  esophageal  carcinoma  in  the  Western  world  has  increased  more  than  600%  since  the  1970s,  mainly  due  to  the  rising  incidence  of  adenocarcinoma.1  Therapeutic  improvements  in  both  early  and  locally  advanced  esophageal  adenocarcinoma  have  been  in  part  based  on  an  understanding  that  gastroesophageal  reflux  (GER)  is  a  precursor  to  esophageal  cancer  leading  to  a  sequence  of  epithelial  changes  from  metaplasia  to  progressive  dysplasia,  ultimately  culminating  in  adenocarcinoma.  This  understanding  coupled  with  technological  advancements  in  endoscopic  and  radiographic  imaging,  have  enhanced  the  surveillance  and  staging  accuracy  of  esophageal  cancer  allowing  us  to  both  identify  patients  at  an  early  stage  more  often,  and  to  select  patients  with  potentially  curable  disease  more  reliably.